Integer Holdings ((ITGR)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Integer Holdings’ latest earnings call painted a nuanced picture, combining robust 2025 performance with a candid acknowledgment of 2026 growing pains. Management stressed that double-digit profit gains, strong cash generation, and an expanding product pipeline support a constructive long-term outlook, even as slower adoption of several key launches weighs on near-term growth and margins.
Broad-Based 2025 Sales Growth
Integer delivered solid top-line momentum in 2025, with reported sales rising 8% to $1.854 billion. Organic sales climbed 6% year over year, showing broad-based strength across the portfolio and underscoring resilient demand despite a mixed macro and procedure environment.
Earnings and EPS See Strong Upside
Profitability outpaced revenue as adjusted net income increased 23% to $226 million, while adjusted EPS rose 21% to $6.40. Management credited higher sales, operating efficiency, and lower interest expense for the step-up in earnings power, reinforcing confidence in the company’s underlying business model.
Margin Expansion and EBITDA Momentum
Integer continued its margin expansion trend, with adjusted EBITDA up 12% to $402 million and adjusted operating income up 13%. The full-year adjusted operating margin improved about 76 basis points to 17.3%, and Q4 margin reached 17.6%, up 74 basis points, highlighting ongoing productivity and mix benefits.
Q4 Delivers Solid Finish to the Year
Fourth-quarter results capped the year with steady growth and margin gains. Sales increased 5% to $472 million, including 2% organic growth, while adjusted EBITDA advanced 11% to $106 million and adjusted EPS jumped 23% to $1.76, demonstrating continued operating leverage.
Healthy Free Cash Flow and Disciplined CapEx
Cash generation remained a core strength, with cash flow from operations of $196 million in 2025. After $91 million of capital expenditures, about 5% of sales, free cash flow totaled $105 million, up $5 million, reflecting disciplined investment while still funding growth initiatives.
Share Repurchases Underscore Capital Discipline
Integer leaned into shareholder returns with a $50 million buyback in Q4 and a new $50 million accelerated share repurchase. Management framed these moves as a signal of confidence in future cash flows and a balanced approach to capital allocation alongside organic and M&A investments.
Leverage Within Target but Debt Still Elevated
The balance sheet sits in a managed but not yet conservative position, with net total debt at $1.19 billion. Net leverage stands at 3.0 times trailing adjusted EBITDA, right at the midpoint of the 2.5 to 3.5 times target range, keeping attention on sustained cash generation to gradually reduce absolute debt.
Product Development Engine Drives Future Growth
Management highlighted a powerful innovation engine, noting product development sales have risen more than 300% since 2017, with about 80% in faster-growing markets. Revenue from customers in introduction or launch phases surged from $10 million in 2018 to roughly $125 million in 2024 and is expected to grow 15% to 20% annually over the next three to five years.
Strategic Investments and Tuck-In Deals Expand Capabilities
Integer is reinforcing its competitive position via targeted capability investments and M&A. The company is funding automation, laser processing, micromachining, prototyping, and facility expansions in locations such as Salem, Va., and Alden, N.Y., while acquisitions like InNeuroQo, Pulse Technologies, and coatings assets broaden its reach in neurovascular, micromachining, and advanced coatings.
Tempered 2026 Outlook Amid Growth Pause
Guidance for 2026 reflects a pause after multiple years of strong growth, with reported sales expected between $1.826 billion and $1.876 billion, down 1% to up 1%. Organic sales are guided to flat to up 3%, and adjusted EPS is forecast at $6.29 to $6.78, a range of down 2% to up 6%, as Integer navigates product-specific and portfolio headwinds.
Slower Adoption of Three New Products Hits 2026
A key swing factor is weaker-than-expected uptake of three new products, two in electrophysiology and one in neuromodulation. These offerings represented nearly 6% of 2025 sales but are now expected to generate significantly lower revenue in 2026, creating a 3% to 4% organic headwind as customers slow adoption and ramp.
Near-Term Margin and Growth Pressure
The company expects 2026 to be a digestion year, with adjusted operating income projected to range from down 5% to up 1%. Q1 operating margin is expected to fall 200 to 250 basis points year on year, and management anticipates organic sales flat to up only low single digits for the year, with first-half revenue down low single digits before a second-half recovery.
Segment Softness in Neuromodulation and CRM Mix
Within the portfolio, Q4 performance in Cardiac Rhythm Management and Neuromodulation was a weak spot, with segment sales down 2% to $167 million. Management cited lower demand from select emerging PMA customers and neuromodulation softness, partly offset by strength in traditional CRM, underscoring mixed dynamics within cardiac and neuro markets.
Portfolio Exit Adds Inorganic Revenue Drag
Beyond new product adoption issues, Integer faces an inorganic headwind from exiting its portable medical portfolio. This completed divestiture is expected to trim roughly 1.3% from 2026 revenue, adding to top-line pressure but consistent with the company’s focus on higher-growth, higher-margin categories.
Working Capital Shift Elevates DSO
Working capital dynamics turned less favorable in Q4 after management chose to limit the use of accounts receivable factoring. Days sales outstanding increased meaningfully, temporarily raising receivables and weighing on cash metrics, but management framed the move as enhancing financial flexibility over the longer term.
Operating Cash Flow Dips Despite Higher FCF
Operating cash flow for 2025 declined $9 million to $196 million, signaling some pressure on cash conversion even as free cash flow edged higher. The combination reflects the interplay of earnings growth, working capital movements, and disciplined but elevated investment spending to support future capacity and innovation.
Sales Cadence and Production Days Distort Quarters
Investors are being warned that quarterly comparisons will be noisy in 2026 due to production-day differences. Management expects about a 5% sales tailwind in Q1 and roughly a 5% headwind in Q4, contributing to early-year margin pressure and complicating simple year-over-year quarterly reads.
2026 Guidance and Path to Recovery
Integer’s 2026 outlook calls for reported sales of $1.826 billion to $1.876 billion and organic sales flat to up 3%, with underlying growth of roughly 4% to 6% when adjusting for the three underperforming products and the portable medical exit. Adjusted EBITDA is guided to $391 million to $415 million, adjusted operating income to $304 million to $324 million, and adjusted EPS to $6.29 to $6.78, with margin pressure in Q1 and improvement in the second half alongside cash flow from operations of $200 million to $220 million and free cash flow of $100 million to $120 million.
Integer’s earnings call ultimately balanced strong execution in 2025 with an unvarnished view of 2026 as a transition year. While softer product ramps, portfolio pruning, and timing effects will constrain near-term results, management underscored its track record of margin expansion, the depth of its pipeline, and disciplined capital deployment as drivers of a return to above-market growth in 2027 and beyond.